Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn-Strides has announced the approval of an ANDA for Rifampin for Injection USP, 600mg/vial. This is the first lyophilized injectable product approval for the joint venture.
Subscribe to our email newsletter
Rifampin for Injection is a semi synthetic antibiotic indicated for the treatment of both tuberculosis and meningococcal carriers.
Akorn-Strides is a joint venture that was formed in 2005 by Akorn, and Strides Arcolab. The primary mission for the joint venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.